These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 18537616)

  • 21. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
    Levin M; Udi Y; Solomonov I; Sagi I
    Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes.
    Winer A; Adams S; Mignatti P
    Mol Cancer Ther; 2018 Jun; 17(6):1147-1155. PubMed ID: 29735645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials.
    Pavlaki M; Zucker S
    Cancer Metastasis Rev; 2003; 22(2-3):177-203. PubMed ID: 12784996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Matrix metalloproteinase inhibitors and cancer: trials and tribulations.
    Coussens LM; Fingleton B; Matrisian LM
    Science; 2002 Mar; 295(5564):2387-92. PubMed ID: 11923519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
    Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
    Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.
    Mitsiades N; Poulaki V; Mitsiades CS; Anderson KC
    Expert Opin Investig Drugs; 2001 Jun; 10(6):1075-84. PubMed ID: 11772236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matrix metalloprotease inhibitors: design from structure.
    Borkakoti N
    Biochem Soc Trans; 2004 Feb; 32(Pt 1):17-20. PubMed ID: 14748704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Matrix metalloproteinase inhibitors--an emphasis on gastrointestinal malignancies.
    Chau I; Rigg A; Cunningham D
    Crit Rev Oncol Hematol; 2003 Feb; 45(2):151-76. PubMed ID: 12604127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matrix metalloproteinases. Novel targets for directed cancer therapy.
    Yu AE; Hewitt RE; Connor EW; Stetler-Stevenson WG
    Drugs Aging; 1997 Sep; 11(3):229-44. PubMed ID: 9303281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview.
    Chaudhary AK; Pandya S; Ghosh K; Nadkarni A
    Mutat Res; 2013; 753(1):7-23. PubMed ID: 23370482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Matrix metalloproteinases as therapeutic targets in cancer.
    Vihinen P; Ala-aho R; Kähäri VM
    Curr Cancer Drug Targets; 2005 May; 5(3):203-20. PubMed ID: 15892620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments.
    Lin H; Xu P; Huang M
    Future Med Chem; 2022 Jan; 14(1):35-51. PubMed ID: 34779649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of matrix metalloproteinase inhibitors in cancer therapy.
    Hidalgo M; Eckhardt SG
    J Natl Cancer Inst; 2001 Feb; 93(3):178-93. PubMed ID: 11158186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MMP inhibitors and cancer treatment trials, limitations and hopes for the future.
    Tlatli R; El Ayeb M
    Arch Inst Pasteur Tunis; 2013; 90(1-4):3-21. PubMed ID: 26012207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies.
    Das S; Amin SA; Jha T
    Eur J Med Chem; 2021 Nov; 223():113623. PubMed ID: 34157437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Matrix metalloproteinase inhibitors as anticancer agents.
    Konstantinopoulos PA; Karamouzis MV; Papatsoris AG; Papavassiliou AG
    Int J Biochem Cell Biol; 2008; 40(6-7):1156-68. PubMed ID: 18164645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural products as a gold mine for selective matrix metalloproteinases inhibitors.
    Wang L; Li X; Zhang S; Lu W; Liao S; Liu X; Shan L; Shen X; Jiang H; Zhang W; Huang J; Li H
    Bioorg Med Chem; 2012 Jul; 20(13):4164-71. PubMed ID: 22658537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
    Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
    Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural studies of matrix metalloproteinases.
    Borkakoti N
    J Mol Med (Berl); 2000; 78(5):261-8. PubMed ID: 10954198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.
    Overall CM; Kleifeld O
    Nat Rev Cancer; 2006 Mar; 6(3):227-39. PubMed ID: 16498445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.